

Barbara Hero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9158642/publications.pdf>

Version: 2024-02-01

66
papers

6,468
citations

136950

32
h-index

110387

64
g-index

67
all docs

67
docs citations

67
times ranked

6757
citing authors

#	ARTICLE	IF	CITATIONS
1	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 289-297.	1.6	1,540
2	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015, 526, 700-704.	27.8	478
3	Neuroblastoma Screening at One Year of Age. <i>New England Journal of Medicine</i> , 2002, 346, 1047-1053.	27.0	381
4	Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2005, 6, 649-658.	10.7	350
5	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. <i>Genome Biology</i> , 2015, 16, 133.	8.8	325
6	Metabolic activity and clinical features of primary ganglioneuromas. <i>Cancer</i> , 2001, 91, 1905-1913.	4.1	281
7	Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97. <i>Journal of Clinical Oncology</i> , 2008, 26, 1504-1510.	1.6	263
8	Mutational dynamics between primary and relapse neuroblastomas. <i>Nature Genetics</i> , 2015, 47, 872-877.	21.4	253
9	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	12.6	213
10	Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	1.2	200
11	Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. <i>Journal of Clinical Oncology</i> , 2014, 32, 3169-3176.	1.6	154
12	Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. <i>Cancer Letters</i> , 2005, 228, 275-282.	7.2	129
13	Role of Surgery in the Treatment of Patients With Stage 4 Neuroblastoma Age 18 Months or Older at Diagnosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 752-758.	1.6	115
14	Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. <i>BMC Cancer</i> , 2016, 16, 542.	2.6	110
15	Neuroblastoma. <i>Drugs</i> , 2000, 59, 1261-1277.	10.9	105
16	Telomerase Activity and Telomerase Subunits Gene Expression Patterns in Neuroblastoma: A Molecular and Immunohistochemical Study Establishing Prognostic Tools for Fresh-Frozen and Paraffin-Embedded Tissues. <i>Journal of Clinical Oncology</i> , 2000, 18, 2582-2592.	1.6	98
17	Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. <i>European Journal of Cancer</i> , 2011, 47, 561-571.	2.8	94
18	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. <i>Clinical Cancer Research</i> , 2015, 21, 1904-1915.	7.0	80

#	ARTICLE	IF	CITATIONS
19	Intensified External-Beam Radiation Therapy Improves the Outcome of Stage 4 Neuroblastoma in Children > 1 Year with Residual Local Disease. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 389-394.	2.0	76
20	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. <i>Klinische Padiatrie</i> , 2017, 229, 147-167.	0.6	76
21	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1084-1093.	6.3	73
22	Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. <i>BMC Cancer</i> , 2017, 17, 520.	2.6	63
23	Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 653-661.	2.5	60
24	Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. <i>European Journal of Cancer</i> , 2017, 72, 177-185.	2.8	59
25	Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28473.	1.5	59
26	Update on Pediatric Opsoclonus Myoclonus Syndrome. <i>Neuropediatrics</i> , 2013, 44, 324-329.	0.6	51
27	LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis. <i>Clinical Cancer Research</i> , 2018, 24, 5772-5783.	7.0	48
28	Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. <i>Nature Communications</i> , 2021, 12, 1269.	12.8	46
29	Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence*. <i>Pediatric Blood and Cancer</i> , 2017, 64, 46-56.	1.5	44
30	PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers. <i>European Radiology Experimental</i> , 2020, 4, 22.	3.4	41
31	Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. <i>Molecular Oncology</i> , 2016, 10, 344-359.	4.6	36
32	Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis?. <i>Medical and Pediatric Oncology</i> , 2000, 35, 683-687.	1.0	35
33	Testicular and paratesticular involvement by metastatic neuroblastoma. <i>Cancer</i> , 2000, 88, 2636-2641.	4.1	33
34	Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. <i>British Journal of Cancer</i> , 2018, 119, 282-290.	6.4	30
35	MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. <i>Oncotarget</i> , 2016, 7, 66344-66359.	1.8	30
36	Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-20.	3.0	29

#	ARTICLE	IF	CITATIONS
37	Pooled RT-qPCR testing for SARS-CoV-2 surveillance in schools - a cluster randomised trial. <i>EClinicalMedicine</i> , 2021, 39, 101082.	7.1	29
38	Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database. <i>Journal of Clinical Oncology</i> , 2014, 32, 1228-1235.	1.6	28
39	The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28359.	1.5	28
40	Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. <i>Medical and Pediatric Oncology</i> , 2000, 35, 651-655.	1.0	27
41	Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. <i>Neoplasia</i> , 2017, 19, 982-990.	5.3	26
42	Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	26
43	Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. <i>Biomedical Reports</i> , 2015, 3, 443-446.	2.0	25
44	Clinical trial of L-carnitine and valproic acid in spinal muscular atrophy type I. <i>Muscle and Nerve</i> , 2018, 57, 193-199.	2.2	23
45	New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 791-6.	0.6	23
46	Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1368-1373.	1.5	22
47	Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. <i>Cancer</i> , 2002, 94, 854-861.	4.1	21
48	German neuroblastoma mass screening study at 12 months of age: statistical aspects and preliminary results. <i>Medical and Pediatric Oncology</i> , 1998, 31, 435-441.	1.0	16
49	Biochemical testing for neuroblastoma using plasma free 3-methyl-dopa, 3-methoxytyramine, and normetanephrine. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28081.	1.5	14
50	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. <i>JAMA Oncology</i> , 2021, 7, 1550.	7.1	14
51	Correction factors for self-selection when evaluating screening programmes. <i>Journal of Medical Screening</i> , 2016, 23, 44-49.	2.3	12
52	A new risk score for patients after first recurrence of stage 4 neuroblastoma aged 18 months at first diagnosis. <i>Cancer Medicine</i> , 2019, 8, 7236-7243.	2.8	12
53	Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 93-98.	0.6	11
54	Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. <i>European Journal of Cancer</i> , 2016, 54, 149-158.	2.8	10

#	ARTICLE	IF	CITATIONS
55	Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry. <i>Frontiers in Oncology</i> , 2020, 10, 617506.	2.8	8
56	Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 17-23.	0.8	7
57	Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB2004. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 683-689.	2.0	6
58	Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients. <i>Medical and Pediatric Oncology</i> , 2001, 36, 199-202.	1.0	5
59	Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab041.	2.9	5
60	Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29038.	1.5	4
61	Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study. <i>JMIR Research Protocols</i> , 2022, 11, e27898.	1.0	3
62	Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis?. , 2000, 35, 683.		2
63	Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification. <i>Cancers</i> , 2021, 13, 4360.	3.7	1
64	Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2021, , e29374.	1.5	1
65	Long-term follow-up of meningeal spread of otherwise stage 4S neuroblastoma without treatment. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26445.	1.5	0
66	IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research Networks. <i>Studies in Health Technology and Informatics</i> , 2016, 228, 287-91.	0.3	0